See the DrugPatentWatch profile for alemtuzumab
When would alemtuzumab’s patents be expected to expire?
Alemtuzumab’s patent life depends on the specific jurisdiction and which patent families you mean (drug substance, drug product, formulation, dosing regimens, and manufacturing). The provided information does not include alemtuzumab’s patent expiry dates by country or by patent number, so the exact “off patent” date can’t be determined from what’s available here.
Does “off patent” mean the same as “no exclusivity”?
Not necessarily. Even after a core compound patent expires, market protection can continue through other patent claims (for example, process or formulation patents) and through regulatory exclusivities, which vary by country. Without jurisdiction- and patent-specific details, you can’t reliably map an “off patent” date to when generics or biosimilars can launch.
How to find the real expiry date you care about (country + biosimilar timing)
To pinpoint the off-patent/biosimilar launch window, you typically need:
- The country (e.g., US, EU, UK, Canada)
- The reference product name in that market (brand and manufacturer)
- The exact patent family you’re tracking (compound vs. formulation/process)
- Whether exclusivity periods apply after patent expiry in that jurisdiction
What I need to give you a precise date
Tell me which market you mean (for example, US or EU) and, if you know it, which product/brand (commonly used with alemtuzumab for MS is Lemtrada). Then I can look up the relevant patent and exclusivity expiry timeline for that jurisdiction.
Sources
No sources were provided in the prompt, so I can’t cite patent expiry information here.